What’s next in CIDP research?
HTML-код
- Опубликовано: 19 июн 2021
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and chronic neurological disorder affecting the peripheral nerves and nerve roots. Characterized by inflammation and demyelination, patients with CIDP experience slowly progressive weakness and impaired sensory function. Peter Van den Bergh, MD, PhD, Université Catholique de Louvain, Brussels, Belgium, discusses the major knowledge gaps and unmet needs in the management of CIDP. The pathophysiology of CIDP is poorly understood and thus, treatments remain suboptimal. More research is needed to understand typical CIDP and its variants in order to develop new therapeutic options. Additionally, Prof. Van den Bergh mentions a similar group of newly discovered neuropathies that are caused by antibodies against nodal and paranodal proteins. Recognizing these disorders is important so that they can be treated effectively. This interview took place during the European Academy of Neurology 2021 congress.